TREND Analysis – Hexo: “Gas in the Tank”

Hexo, like Aphria, does not break Inventory into Work in Progress or Finished Goods in their notes or MDA. Hexo always had minor Medical sales and was looking to adult recreational to be their core business. Bio Assets has been growing the last two Q's, and Inventory has certainly also shown growth. Inventory, like Aphria, is very linear but it is tough to tell if they will be able to keep up the sales pace without knowing the FG available for sale.. The Sales delta is exceeding the Inventory Delta in the last Q.

Continue Reading
Valens GroWorks – Structure and Current State – 03/19

Busy earnings days lately. These guys came out on March 13th. Much more structures to come over the next while. I’ve been interested in $VGW since I came across them in late 2017, and did rundowns on them in both of the Dive Bar Pub Crawls past two years running. Here's 2017, and here's 2018's. There wasn’t much cloth to make a suit out of then. Early formation, in the process of raising capital, building out, and awaiting licensing. Standard fare for the ‘early’ entrants. Now we’ve got another year of financials, time to put Molly Gladys on the lap (Molly went back to…

Continue Reading
1933 Industries – Structure and Current State – 04/19

Busy earnings day on April 1st - And 1933 is one of them. I've got many more structures to come. I’ve been interested in $TGIF since I came across them in late 2017, as well as 2018 when I did rundowns on them in both of the Dive Bar Pub Crawls past two years running. TGIF has a back story that I never quite got a handle on…which…while important to me at the time...has faded into the rearview of relevance. 2 years ago, it was important to me because it was not only my first pass, but also to get insights into the ‘jockey’…

Continue Reading
Charlotte’s Web Holdings – Structure and Current State – 12/19

Charlotte’s Web Holdings focuses only on CBD/hemp exposure - they don’t offer psychoactive cannabinoids. They claim though that flavonoids and terpenes and their proprietary mixtures of them offer an advantage over straight CBD. The CBD market is already competitive, and product differentiation would appear to be a competitive advantage. Probably no other company has benefitted as much from the US Farm Bill more than CWEB has. Their share price has been a straight out bull run, and is an outfit that hasn’t struggled to maintain IPO price. At all. To the financials: Relatively cash deepUsing all the product they can get. Inventory low to…

Continue Reading
Close Menu